双特异性抗体在复发难治多发性骨髓瘤中的治疗进展

Progress of bispecific antibodies in relapsed/refractory multiple myeloma

近年来,针对多发性骨髓瘤(multiple myeloma,MM)细胞上特异性表面抗原的单克隆抗体越来越多应用于治疗复发难治多发性骨髓瘤(relapsed/refractory multiple myeloma,R/RMM)。双特异性抗体(bispecific antibodies,BsAb)与肿瘤细胞抗原和T细胞上的CD3结合,激活T细胞并靶向杀伤肿瘤细胞,有针对B细胞成熟抗原(B cell maturation antigen,BCMA)靶点和非BCMA靶点如GPRC5D和FcRH5的多种BsAb,显示各自的药代动力特点以及相关疗效和不良反应,多项临床试验研究已证实其在R/RMM患者中具有可喜的临床有效性和安全性。

In recent years,monoclonal antibodies against specific surface antigens on multiple myeloma(MM)cells have been increasingly used to treat relapsed and refractory multiple myeloma(R/RMM).Bispecific antibodies(BsAb)combine with tumor cell antigens and CD3 on T cells to activate T cells and target tumor cells.There are a variety of BsAb targeted at B cell mature antigen(BCMA)targets and non BCMA targets,such as GPRC5D and FcRH5,showing their respective pharmacokinetic characteristics and related efficacy and adverse reactions.A number of clinical trials have confirmed that they have promising clinical efficacy and safety in R/RMM patients.